Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
Original Publication Date
Article Source
External Web Content
Abstract BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML…